Showing 1 - 14 results of 14 for search 'Reda, G', query time: 0.14s
Refine Results
-
1
New Anticancer Theobromine Derivative Targeting EGFR<sup>WT</sup> and EGFR<sup>T790M</sup>: Design, Semi-Synthesis, In Silico, and In Vitro Anticancer Studies by Eslam B. Elkaeed, Reda G. Yousef, Hazem Elkady, Aisha A. Alsfouk, Dalal Z. Husein, Ibrahim M. Ibrahim, Ahmed M. Metwaly, Ibrahim H. Eissa
Published 2022-09-01
Article -
2
Anticancer derivative of the natural alkaloid, theobromine, inhibiting EGFR protein: Computer-aided drug discovery approach. by Ibrahim H Eissa, Reda G Yousef, Eslam B Elkaeed, Aisha A Alsfouk, Dalal Z Husein, Ibrahim M Ibrahim, Mohamed S Alesawy, Hazem Elkady, Ahmed M Metwaly
Published 2023-01-01
Article -
3
New Theobromine Apoptotic Analogue with Anticancer Potential Targeting the EGFR Protein: Computational and In Vitro Studies by Ibrahim H. Eissa, Reda G. Yousef, Eslam B. Elkaeed, Aisha A. Alsfouk, Dalal Z. Husein, Ibrahim M. Ibrahim, Ahmed Ismail, Hazem Elkady, Ahmed M. Metwaly
Published 2024-03-01
Article -
4
-
5
Computer-Assisted Drug Discovery of a Novel Theobromine Derivative as an EGFR Protein-Targeted Apoptosis Inducer by Ibrahim H Eissa, Reda G Yousef, Eslam B Elkaeed, Aisha A Alsfouk, Dalal Z Husein, Ibrahim M Ibrahim, Hesham A El-Mahdy, Hazem Elkady, Ahmed M Metwaly
Published 2023-12-01
Article -
6
Design, Synthesis, Docking, DFT, MD Simulation Studies of a New Nicotinamide-Based Derivative: In Vitro Anticancer and VEGFR-2 Inhibitory Effects by Eslam B. Elkaeed, Reda G. Yousef, Hazem Elkady, Ibraheem M. M. Gobaara, Bshra A. Alsfouk, Dalal Z. Husein, Ibrahim M. Ibrahim, Ahmed M. Metwaly, Ibrahim H. Eissa
Published 2022-07-01
Article -
7
Design and In Silico and In Vitro Evaluations of a Novel Nicotinamide Derivative as a VEGFR-2 Inhibitor by Ibrahim H. Eissa, Muhammad Abd ElGayed Bkrah, Reda G. Yousef, Hazem Elkady, Eslam B. Elkaeed, Bshra A. Alsfouk, Ibrahim M. Ibrahim, Ahmed M. Metwaly, Dalal Z. Husein
Published 2024-01-01
Article -
8
(<i>E</i>)-<i>N</i>-(3-(1-(2-(4-(2,2,2-Trifluoroacetamido)benzoyl)hydrazono)ethyl)phenyl)nicotinamide: A Novel Pyridine Derivative for Inhibiting Vascular Endothelial Growth Factor... by Reda G. Yousef, Hazem Elkady, Eslam B. Elkaeed, Ibraheem M. M. Gobaara, Hanan A. Al-ghulikah, Dalal Z. Husein, Ibrahim M. Ibrahim, Ahmed M. Metwaly, Ibrahim H. Eissa
Published 2022-11-01
Article -
9
Computer-assisted drug discovery (CADD) of an anti-cancer derivative of the theobromine alkaloid inhibiting VEGFR-2 by Ibrahim H. Eissa, Reda G. Yousef, Mostafa A. Asmaey, Hazem Elkady, Dalal Z. Husein, Aisha A. Alsfouk, Ibrahim M. Ibrahim, Mohamed A. Elkady, Eslam B. Elkaeed, Ahmed M. Metwaly
Published 2023-12-01
Article -
10
Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2 by Reda G. Yousef, Wagdy M. Eldehna, Alaa Elwan, Abdelaziz S. Abdelaziz, Ahmed B. M. Mehany, Ibraheem M. M. Gobaara, Bshra A. Alsfouk, Eslam B. Elkaeed, Ahmed M. Metwaly, Ibrahim H. Eissa
Published 2022-06-01
Article -
11
Anti-cancer and immunomodulatory evaluation of new nicotinamide derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: in vitro and in silico studies by Reda G. Yousef, Alaa Elwan, Ibraheem M. M. Gobaara, Ahmed B. M. Mehany, Wagdy M. Eldehna, Souad A. El-Metwally, Bshra A. Alsfouk, Eslam B. Elkaeed, Ahmed M. Metwaly, Ibrahim H. Eissa
Published 2022-12-01
Article -
12
A Theobromine Derivative with Anticancer Properties Targeting VEGFR‐2: Semisynthesis, in silico and in vitro Studies by Prof. Ibrahim H. Eissa, Reda G. Yousef, Dr. Hazem Elkady, Dr. Eslam B. Elkaeed, Dr. Aisha A. Alsfouk, Dr. Dalal Z. Husein, Ibrahim M. Ibrahim, Prof. Mohamed M. Radwan, Prof. Ahmed M. Metwaly
Published 2023-10-01
Article -
13
Discovery of New VEGFR-2 Inhibitors: Design, Synthesis, Anti-Proliferative Evaluation, Docking, and MD Simulation Studies by Eslam B. Elkaeed, Reda G. Yousef, Mohamed M. Khalifa, Albaraa Ibrahim, Ahmed B. M. Mehany, Ibraheem M. M. Gobaara, Bshra A. Alsfouk, Wagdy M. Eldehna, Ahmed M. Metwaly, Ibrahim H. Eissa, Mohamed Ayman El-Zahabi
Published 2022-09-01
Article -
14
Phase III, randomized, placebo-controlled trial of CC-486 (Oral Azacitidine) in patients with lower-risk myelodysplastic syndromes by Garcia-Manero, G, Santini, V, Almeida, A, Platzbecker, U, Jonasova, A, Silverman, LR, Falantes, J, Reda, G, Buccisano, F, Fenaux, P, Buckstein, R, Diez Campelo, M, Larsen, S, Valcarcel, D, Vyas, P, Giai, V, Olíva, EN, Shortt, J, Niederwieser, D, Mittelman, M, Fianchi, L, La Torre, I, Zhong, J, Laille, E, Lopes de Menezes, D, Skikne, B, Beach, CL, Giagounidis, A
Published 2021Journal article